Objective: Peripheral artery disease (PAD) is an increasing health concern with rising incidence globally. Previous studies have shown an association between PAD incidence and depression. The objective of the study was to determine the association of comorbid depression with PAD outcomes (amputation and all-cause mortality rates) in veterans.
Peripheral artery disease (PAD) is a significant health issue with a rising incidence globally. 1 Patients with PAD continue to be threatened with an unacceptably high risk for cardiovascular (CV) events 2, 3 and suffer significant morbidity related to claudication and limb loss, resulting in a decreased quality of life. 4, 5 Inflammation and endothelial dysfunction play an important role in the pathophysiologic process of PAD. Whereas circulating inflammatory markers are associated with disease progression and mortality, 6 impaired endothelial function independently predicts future CV events. 7, 8 More recent evidence suggests that depression, which is associated with inflammation and endothelial dysfunction, 9 should join smoking, diabetes, hyperlipidemia, and hypertension as a recognized risk factor for PAD. 10, 11 Although there has been recognition of the role of depression in the development and progression of CV disease, the relationship remains less well characterized in the PAD population. [12] [13] [14] [15] [16] It has been previously demonstrated that patients with depressive symptoms had a higher risk of prospective PAD occurrence during a period of 7 years. 10 Depression in the setting of PAD also leads to decreased functional outcomes and walking capacity, 17, 18 worse patency rates after revascularization, 19 and increased progression of PAD. 20 McDermott et al 21 also recently demonstrated a higher association for all-cause mortality and CV mortality in PAD patients with depression. The impact of comorbid depression on the risk of amputation in patients with PAD is less understood. In addition, the effect of antidepressant treatment on outcomes in this population has not been studied. This analysis sought to characterize the association of comorbid depression and of antidepressant treatment with the risk of limb loss and mortality in the PAD population.
METHODS
Sample and database. Incident PAD patients were identified by Veterans Health Administration data from 2003 to 2014 (N ¼ 155,647) using a validated algorithm (International Classification of Diseases, Ninth Revision diagnosis code for PAD and any one of three criteria: two ankle-brachial indices in 14 months, two visits to a vascular surgeon or clinic in 14 months, or any PAD procedure code). 22 Patients with a PAD diagnosis code in the preceding 2 years (2000-2002) were excluded to capture incident cases. A comprehensive list of covariates was obtained: age at PAD diagnosis (estimated using date of birth), sex, race, and socioeconomic status (SES; median household income of the patient's most recent residential ZIP code tabulation area); body mass index; serum creatinine concentration; and comorbidities, such as diabetes mellitus, hypertension, coronary artery disease (CAD), chronic obstructive pulmonary disease, congestive heart failure (CHF), atrial fibrillation, carotid disease, chronic kidney disease, and end-stage renal disease.
Smoking status (using a validated method 23 ) and use of the following medications were assessed: antiplatelet agents, statins, cilostazol, antiglycemics, and antidepressants. All covariates were measured within a 6-month time frame (before or after) of the PAD diagnosis date from the national Veterans Affairs (VA) Corporate Data Warehouse and VA Medical SAS administrative databases.
Study exposure and outcome. Comorbid depression was defined as having an International Classification of Diseases, Ninth Revision diagnosis code of 293.83, 296.2x, 296.3x, 300.4, or 311 either at least once in an inpatient setting or at least twice within 14 months in an outpatient setting within 6 months before or after the PAD diagnosis date (Supplementary Table I , online only; definition based on data from prior VA studies). [24] [25] [26] Antidepressant use was obtained from the VA pharmacy files for prescriptions filled at a VA pharmacy as well as from the non-VA medication file, which holds data on medications filled by veterans and covered by the VA regardless of where the prescription was filled. Antidepressants were classified as selective serotonin reuptake inhibitors (SSRIs), selective norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, and others (Supplementary Table I , online only). Patients could be taking multiple medications, but no differentiation was made between subjects taking one or more drugs within a given category. In patients without a diagnosis of depression, we did not explore the indication for use of antidepressant medications for the purpose of this analysis (such as smoking cessation, posttraumatic stress disorder [PTSD], obsessive-compulsive disorder [OCD], anxiety disorders, social phobia, panic disorder, bulimia nervosa, premenstrual dysphoric disorder, borderline personality disorder, and obesity). The outcomes of interest were incident major amputation (below and above the knee) and death after the PAD diagnosis date. Specific amputation codes are defined in Supplementary Table I (online only) ; long-term survival of the cohort was extracted from the VA Vital Status File. The follow-up continued through outcome occurrence, death (censoring event in the case of amputations), or December 31, 2015 (whereupon the subject was censored). Patients with prior amputations were included in the analysis, but incident amputation was defined as the first amputation after the PAD diagnosis date.
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Statistical analysis. Demographic and clinical variables were assessed for the entire cohort and stratified by depression. Continuous variables were expressed as means (6 standard deviations) or as medians (6 interquartile ranges) if they were not normally distributed. These were compared using independent sample t-tests or the Wilcoxon rank sum test. Discrete variables were compared using c 2 tests for proportions. Proportions of missing data were also calculated with no variables missing >15% except smoking (36.6%). Kaplan-Meier curves were used to compare overall survival by depression status. Cumulative incidence function curves, instead of Kaplan-Meier curves, were used to compare amputation-free survival (AFS) by depression status to account for death as a competing risk for patients because it precludes them from experiencing an amputation. Treating death as independent or noninformative censoring (as is done in Kaplan-Meier curves) would produce overestimation of the probability of amputation. Cause-specific Cox proportional hazards regression models were then constructed to calculate adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for amputation and death by depression status alone and then while allowing interaction by antidepressant use. The models adjusted for the covariates listed in Table I . All variables were found to meet the proportional hazards assumption through log-log survival curves for amputation and mortality. Wald confidence limits were constructed for all HRs. The statistical analysis was done using SAS version 9.4 (SAS Institute, Cary, NC). Two-sided P values <.05 were considered statistically significant. This study was approved by the Emory University Institutional Review Board and Atlanta VA Medical Center Research and Development Committee. Informed consent was waived for a retrospective cohort study design with no human subject contact and minimal privacy risks.
RESULTS
The cohort consisted of 155,647 veterans with incident clinical PAD and a median follow-up of 5.9 years. The majority of the cohort was male (97.9%), with a mean age of 66.7 years (standard deviation, 9.9). There were 9517 amputations and 63,287 deaths identified during the follow-up period. Of the total, 24,895 (16.0%) carried a diagnosis of depression. The demographics of the cohort are listed in Table I Unadjusted associations of depression with amputation and mortality. In unadjusted Cox models, the risk of amputation was 32% higher (HR, 1.32; 95% CI, 1.25-1.39) for patients with depression compared with those without. Depression had no association with mortality risk (HR, 1.02; 95% CI, 0.99-1.04) in unadjusted analysis. In addition, the association of depression with amputation and mortality was further explored by stratifying by use of antidepressants. Cumulative incidence function curves showed that AFS among those with depression was worse for those not taking antidepressants compared with those without depression as well as those with depression taking antidepressants (Gray test, P < .0001; Fig 1) . In terms of absolute risk, the 1-year, 3-year, and 5-year AFS for patients with depression and not taking antidepressants was 93.6%, 91.5%, and 89.8%, respectively, compared with 97.8%, 96.3%, and 95.2% AFS for patients without depression, respectively. Patients with depression taking antidepressants or those without a diagnosis of depression but taking antidepressants for other indications still had a significantly worse AFS compared with those without depression (P < .001). The absolute AFS at 1 year, 3 years, and 5 years was 96.9%, 95.3%, and 94.0% for depressed patients taking antidepressants and 97.4%, 95.7%, and 94.5% for those taking antidepressants for other indications but better than for those with untreated depression. With respect to mortality (Fig 2) , patients with untreated depression had a significantly lower overall survival (89.5% at 1 year, 76.3% at 3 years, and 64.3% at 5 years) compared with the other three groups: patients without depression (94.4% at 1 year, 83.30% at 3 years, and 71.5% at 5 years), patients taking antidepressants for other indications (94.0% at 1 year, 82.2% at 3 years, and 70.9% at 5 years), and those with depression but taking antidepressants (94.0% at 1 year, 81.9% at 3 years, and 70.1% at 5 years; P < .001). Patients with depression taking antidepressants had no significant difference in mortality compared with those without depression, whether taking antidepressants or not (P ¼ .08).
Adjusted associations of depression with amputation and mortality. After adjustment for covariates (outlined in Methods) in a Cox model (Table II) , the hazard of death was 17% higher for depressed subjects vs nondepressed subjects (HR, 1.17; 95% CI, 1.14-1.20). In addition, the risk of amputation was 13% higher for depressed subjects (HR, 1.13; 95% CI, 1.07-1.19). Female sex (HR for death, 0.82; HR for amputation, 0.44), higher body mass index (HR for death, 0.97; HR for amputation, 0.96), statin use (HR for death, 0.77; HR for amputation, 0.74), antiplatelet use (HR for death, 0.71; HR for amputation, 0.87), and cilostazol use (HR for death, 0.92; HR for amputation, 0.77) were all associated with lower risks of death and amputation. Black race (vs white) was a significant predictor for increased risk of amputation (HR, 1.42) but had a survival advantage in terms of mortality (HR, 0.83), whereas low SES (HR for death, 1.37; HR for amputation, 1.15) had independently higher risk of mortality and amputation. Traditional atherosclerotic risk factors were associated with higher risk of mortality and amputation, such as diabetes (HR for death, 1.18; HR for amputation, 1.74), hypertension (HR for death, 1.11; HR for amputation, 1.27), and current smoking (HR for death, 1.28; HR for amputation, 1.17). Of note, CHF (HR for death, Interaction of depression and use of antidepressants and its association with amputation and mortality. There was a statistically significant interaction between depression and antidepressant medications with regard to amputation (P < .0001; Table III; Supplementary  Table II , online only). After an interaction term was added to stratify by antidepressant use, depressed subjects not taking antidepressants had significantly elevated hazards of amputation (HR, 1.42; 95% CI, 1.27-1.58) relative to nondepressed patients not taking any antidepressants. Depressed patients taking antidepressants (HR, 1.08; 95% CI, 1.03-1.14) as well as nondepressed patients taking antidepressants for other indications (HR, 1.10; 95% CI, 1.03-1.17) had a moderately higher risk of amputations compared with the nondepressed PAD patients but not to the same degree as with untreated depression. Mortality risk was 18% to 25% higher for patients with depression (with or without use of antidepressants) or taking antidepressants for other indications compared with those who were not depressed and not needing antidepressants for any other diagnoses. However, between these three groups, there was no significant difference in mortality for PAD patients A B 
DISCUSSION
In this large cohort of veterans with incident PAD, this study found that patients with comorbid depression had a significantly higher risk of amputation (13%) and all-cause mortality (17%) than PAD patients without depression, after adjustment for covariates. There was a significant interaction of antidepressant use on the risk of amputation in PAD patients with depression but not so much on mortality. Taking prescription antidepressants for depression was associated with a significantly lowered risk for amputation (10% higher than for nondepressed patients not taking antidepressants) in contrast to those with depression and not taking antidepressants (42% higher than for nondepressed patients not taking antidepressants). Interestingly, patients taking antidepressants for other diagnoses (eg, PTSD, OCD, anxiety) were also at a slightly higher risk of amputation (8% higher than for nondepressed patients not taking antidepressants). Having any diagnosis of depression or the need for antidepressants increased the mortality risk by 18% to 25% in the PAD cohort. The data underline the negative impact of depression on prognosis of patients with PAD. Although causality is not established, the results presented also highlight the importance of further investigating depressive treatment options in the care of PAD patients suffering from depression.
Association between PAD and depression. Whereas the evidence base for the relationship between depression and heart disease is growing, [12] [13] [14] [15] [16] are at increased risk for CV events and progression of contralateral PAD after undergoing lower extremity revascularization. The results of this study provide further evidence of a clear association between depression and PAD by demonstrating that depression is a significant risk factor for the end points of amputation and mortality in the management of PAD. In the cohort, depressed patients initially did not appear to have any mortality difference in unadjusted Kaplan-Meier analysis. However, they were on average younger than nondepressed patients with more prevalence of current smoking and other comorbidities, such as diabetes, CAD, CHF, chronic obstructive pulmonary disease, and kidney disease. On adjustment for these confounders, there was a strong association in terms of 17% increased risk of mortality with depression. To our knowledge, it is the first time that the association of depression with PAD outcomes has been demonstrated in such a large cohort, and we also demonstrate an intriguing association between antidepressant treatment and amputation. These findings deserve further investigation as they have the potential to improve health outcomes in a large population.
Mechanistic pathways. The association between depression and PAD adverse outcomes may be explained by a composite of behavioral and biologic mechanisms as has been previously reported. 10 In the Cardiovascular Health Study, 25% of CV mortality in patients with depression was attributed to physical inactivity, 31 supporting findings by Whooley et al 32 that
adjusting for behavioral mediators, particularly physical inactivity, eliminated the 31% association between depression and CV events in patients with stable CAD. In a prospective cohort of veterans, the Heart and Soul Study found that 12% of patients with depressive 35, 36 and platelet hyperaggregability related to elevated plasma levels of platelet factor 4 and b-thromboglobulin.
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Endothelial dysfunction associated with reduced levels of endothelial progenitor cells and attenuated flow-mediated dilation [40] [41] [42] as well as a heightened inflammatory response indicated by elevated inflammatory markers, such as C-reactive protein, tumor necrosis factor a, and interleukin 6, may also be involved. [43] [44] [45] [46] Investigations thus far support a relative contribution of both physiologic and behavioral factors driving the association between depression and vascular disease. The results support the role of more research to better understand the mechanisms involved in the reported association to help direct treatment regimens.
Role of antidepressants. The findings from this study suggest that antidepressant therapy may alleviate the morbid burden of depression on PAD outcomes related to limb loss but not mortality, although causality remains to be determined. Possible explanations for these findings include a physiologic effect of antidepressants on limb loss in PAD (true causality) and residual confounding from care utilization. In terms of health care access and utilization, depressed patients were more likely to be white, to present with tissue loss at PAD diagnosis, and to have a slightly higher chance of being in the lowest SES stratum. However, they had higher prescription rates of antiplatelet, statin, and diabetic medications but lower prescription of cilostazol. Despite adjustment for these markers, there was significant effect modification of amputation risk by treatment of depression. Furthermore, nondepressed patients who were taking antidepressants for other indications had a moderately higher risk of amputations compared with the nondepressed PAD patients (HR, 1.10), which was similar for treated depressed patients (HR, 1.08). This group of patients likely had other mental illnesses necessitating use of antidepressants. There are newer studies suggesting the increased vascular dysfunction in disorders such as PTSD that are treated with antidepressants. 47, 48 Some of the mechanisms of action of antidepressants involve pathophysiologic processes in PAD and CV diseases, such as platelet activation. 49 In fact, the impairment of primary hemostasis induced by SSRIs may result in a reduction in thrombotic risk. 50 The study's findings bring more data in an area where controversy related to the effect of antidepressants on the incidence of CV events remains. In fact, several randomized studies have taken place on the use of antidepressants in patients with CV disease, with mixed results. 51 It is thought that a large trial on the use of antidepressant therapy vs placebo would bring ethical concerns because depression in itself requires treatment. With regard to PAD, studies examining the role of antidepressants are limited (or nonexistent), and this study qualifies the potential benefit that antidepressants may have in PAD patients with depression. Future studies are needed to support this finding that antidepressants are related to decreased limb loss in patients with PAD with depression and to determine whether depression should be more aggressively treated in patients with CV disease. Future studies are also needed to ascertain the risk of other mental illnesses and their treatment (PTSD, OCD, anxiety) on PAD outcomes.
Limitations. This study has several limitations. First, this is an observational study using administrative data, which come from clinical care records, and the analysis may be susceptible to residual confounding. A significant effort was made to account for accurate PAD diagnosis as well as performing a comprehensive Cox model. In addition, careful handling of missing data was done to minimize and to investigate the possibility of bias. Right censoring was done at occurrence of outcomes (death and amputation, which are fairly accurately reported, given the multiple data sources used) or the end of the follow-up in the study, but we could miss the occurrence of amputations in a small percentage of patients who sought all their care outside the VA system and did not use VA coverage (fee basis). The study did not assess for severity of depression or response to treatment, which represents another limitation. With regard to treatment of depression, it is possible that patients treated for depression were treated with psychotherapy that was not captured in the analysis. Among patients taking antidepressants, we could not assess medication compliance. If there is a direct medication effect on amputation risk, data on compliance could help delineate that effect. We also did not investigate the indications for use of antidepressants in patients who did not carry a diagnosis of depression. We therefore cannot comment on the role of other mental illnesses on PAD amputation risk, but it would be something to explore in future manuscripts. In addition, the study is based on Veterans Health Administration data, and it is overwhelmingly composed of male patients. Therefore, results may differ in a non-VA or female population.
CONCLUSIONS
The clinical significance of comorbid depression on PAD is becoming more recognized. The findings of this study demonstrate that PAD patients with depression are at a higher risk of long-term death and amputation and that amputation risk may be modifiable on the basis of treatment of depression. The 2016 American Heart Association guidelines for the management of patients with lower extremity PAD have called for new medical therapies for patients with PAD. 52 We suggest raised awareness related to mental health issues in this population. We also press for continued investigation into mechanisms involved in worse outcomes for those with depression (mechanisms specific to both overall survival and limb salvage) as well as treatment strategies to alleviate this risk. 
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